UBS Group lowered shares of Pfizer (NYSE:PFE – Get Rating) from a buy rating to a neutral rating in a research note published on Thursday, MarketBeat reports. They currently have $47.00 price objective on the biopharmaceutical company's stock, down from their previous price objective of $55.00.
Several other equities research analysts have also recently commented on the company. Bank of America cut Pfizer from a buy rating to a neutral rating and set a $60.00 target price on the stock. in a research note on Wednesday, January 4th. JPMorgan Chase & Co. set a $50.00 target price on Pfizer in a research note on Wednesday, January 18th. Barclays upped their price objective on Pfizer from $44.00 to $49.00 and gave the stock an equal weight rating in a research note on Wednesday, November 2nd. SVB Leerink upped their price objective on Pfizer from $48.00 to $49.00 and gave the stock a market perform rating in a research note on Thursday, November 3rd. Finally, StockNews.com initiated coverage on Pfizer in a research note on Wednesday, October 12th. They set a strong-buy rating on the stock. Seven analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $52.33.
Get
Pfizer alerts:
Pfizer Trading Down 1.0 %
NYSE:PFE opened at $43.79 on Thursday. Pfizer has a fifty-two week low of $41.44 and a fifty-two week high of $56.32. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.37. The stock has a market capitalization of $245.81 billion, a PE ratio of 8.42, a price-to-earnings-growth ratio of 1.09 and a beta of 0.67. The business's 50-day simple moving average is $49.45 and its 200-day simple moving average is $47.95.
Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the consensus estimate of $1.47 by $0.31. The firm had revenue of $22.64 billion for the quarter, compared to analysts' expectations of $21.04 billion. Pfizer had a return on equity of 43.95% and a net
margin of 29.81%. Sell-side analysts expect that Pfizer will post 6.47 earnings per share for the current fiscal year.
Pfizer Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 3rd. Investors of record on Friday, January 27th will be paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.75%. The ex-dividend date of this dividend is Thursday, January 26th. This is a boost from Pfizer's previous quarterly dividend of $0.40. Pfizer's dividend payout ratio is 31.54%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. RB Capital Management LLC grew its holdings in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company's stock valued at $282,000 after buying an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. grew its holdings in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company's stock valued at $1,868,000 after buying an additional 400 shares in the last quarter. United Bank grew its holdings in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company's stock worth $2,416,000 after purchasing an additional 290 shares in the last quarter. Ergoteles LLC grew its holdings in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company's stock worth $1,903,000 after purchasing an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company's stock worth $69,238,000 after purchasing an additional 79,887 shares in the last quarter. 67.62% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
(Get Rating)
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Further Reading
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
